q1 adjusted non-gaap earnings per share $2.52.
q1 revenue rose 58 percent to $6.9 billion.
for q2 2021, company anticipates that non-gaap core revenue growth will be in mid-20 percent range.
for full year 2021, company now anticipates that non-gaap core revenue growth rate including cytiva will be in high-teens percent range.
